Loading
A phase 2 trial of Ruxolitinib, Capecitabine, Regorafenib in colorectal cancer, run by Incyte Corporation, active and no longer recruiting.
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib is a phase 2 interventional study registered as NCT02955940 by Incyte Corporation, with 10 participants enrolled, started 2016-11-30 and due to reach its primary completion in 2027-09-30. Interventions recorded: Ruxolitinib, Capecitabine, Regorafenib. Conditions listed: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte.
Shares Ruxolitinib, Incyte.
Shares Incyte, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/